News round-up for 11-15 September by DDW Digital Content Editor Diana Spencer.
Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development.
The headlines:
Pharma must embrace an AI future says new report
Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com.
First patient dosed in Phase Ib study in small cell lung cancer
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC).
£1.8 million raised to accelerate quantum drug discovery
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes.
Collaboration to discover novel targeted radioligand therapies
Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.
Phase I trial of next-generation srRNA rabies vaccine
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. The trial, which marks the first time a human has been dosed with Replicate’s srRNA technology, will serve as a benchmark for utility in this indication and other complex infectious diseases.
